

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listing of claims in the application.

Claims 1-86: (Cancelled).

87. (Currently Amended) An isolated polypeptide capable of specific binding to factor VIII and comprising a heavy chain variable region of a human antibody with factor VIII specificity and a light chain variable region of a human antibody, wherein the heavy chain variable region comprises a sequence selected from the group consisting of SEQ. ID. NO: 23, ~~SEQ. ID. NO: 24~~, SEQ. ID. NO: 25, ~~SEQ. ID. NO: 26~~, SEQ. ID. NO: 27, SEQ. ID. NO: 28, ~~SEQ. ID. NO: 31~~, SEQ. ID. NO: 32, ~~SEQ. ID. NO: 33~~, SEQ. ID. NO: 34, ~~SEQ. ID. NO: 35~~, SEQ. ID. NO: 36, ~~SEQ. ID. NO: 37~~, SEQ. ID. NO: 38, SEQ. ID. NO: 51, ~~SEQ. ID. NO: 52~~, and SEQ. ID. NO: 53.

88. (Cancelled).

89. (Currently Amended) The isolated polypeptide of claim 87, which is capable of interfering with the activity of factor VIII inhibitors, and wherein the heavy chain variable region comprises a sequence ~~sequence~~ selected from the group consisting of SEQ. ID. NO: 25, SEQ. ID. NO: 23, SEQ. ID. NO: 27, and SEQ. ID. NO: 28.

90. (Previously Presented) The isolated polypeptide of claim 87, wherein the heavy chain variable region comprises a sequence selected from the group consisting of SEQ. ID. NO: 32, SEQ. ID. NO: 34, SEQ. ID. NO: 36, SEQ. ID. NO: 38, SEQ. ID. NO: 51 and SEQ. ID. NO: 53.

91. (Previously Presented) The isolated polypeptide of claim 87, wherein said polypeptide is a single chain Fv fragment.

92. (Previously Presented) The isolated polypeptide of claim 87, wherein said polypeptide is an antibody.

93. (Previously Presented) The isolated polypeptide of claim 92, wherein said antibody is an IgG.

94. (Previously Presented) The isolated polypeptide of claim 87, wherein said polypeptide specifically binds the heavy chain of factor VIII.

95. (Previously Presented) The isolated polypeptide of claim 87, wherein said polypeptide specifically binds a domain of the heavy chain of factor VIII consisting of the A1 domain, the A2 domain and the B domain of factor VIII.

96. (Previously Presented) The isolated polypeptide of claim 87, wherein said polypeptide specifically binds the light chain of factor VIII.

97. (Previously Presented) The isolated polypeptide of claim 87, wherein said polypeptide specifically binds a region of the light chain of factor VIII consisting of the A3 domain, the C1 domain and the C2 domain of factor VIII.

98. (Previously Presented) A pharmaceutical composition for the treatment of factor VIII inhibition in a human individual, comprising the isolated polypeptide according to claim 87 together with a pharmaceutically acceptable carrier.

99. (Currently Amended) A pharmaceutical composition for the treatment of factor VIII inhibition in a human individual, comprising the isolated polypeptide according to claim 90 ~~claim 88~~ together with a pharmaceutically acceptable carrier.

100. (Previously Presented) A pharmaceutical composition for the treatment of factor VIII inhibition in a human individual, comprising the isolated polypeptide according to claim 89 together with a pharmaceutically acceptable carrier.